CureVac Denies Takeover Reports As It Slates Phase I Coronavirus Vaccine Study For Early Summer

The German biotech firm has denied receiving any offer from the Trump administration in a wide-ranging conference call that also addressed recent changes at the top, its clinical timeline for a coronavirus vaccine and new funds from the European Commission to boost production.  

Coronavirus
• Source: Shutterstock

CureVac AG has stressed that it knew nothing of any offers from the White House for its coronavirus vaccine candidate after a fevered few days for the German biotech firm that have seen two changes of CEO, as it found itself at the center of a media storm in the midst of a pandemic.

“There is no takeover offer from the White House or governmental authorities neither to the technology or to CureVac as...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip